Fred Hutch Launches $15 Million Trial Comparing Stem Cell Transplant vs. Non-Transplant Therapy in Older AML Patients
核心洞察
Fred Hutch Cancer Center (搜索) researchers will lead an 18-center U.S. clinical trial comparing stem cell transplantation with non-transplant therapy in older adults with acute myeloid leukemia (搜索) (AML).
The study will enroll approximately 800 patients after they reach remission, with Dr. Mohamed Sorror serving as principal investigator.
Researchers estimate that for roughly one-third to one-half of older AML patients, it remains unclear which treatment approach is superior.
Fred Hutch Cancer Center (搜索) researchers will lead a clinical trial studying treatment options for older adults with acute myeloid leukemia (搜索) (AML), an aggressive blood cancer. The principal investigator is Dr. Mohamed Sorror, a hematologist-oncologist and clinical researcher with Fred Hutch and the University of Washington School of Medicine (搜索).
The 18-center U.S. study will enroll about 800 patients to compare stem cell transplantation with non-transplant therapy after patients reach remission. Researchers estimate that, for roughly one-third to one-half of older AML patients, it is currently unclear which treatment approach is better.
Addressing an Unmet Clinical Question
The trial directly targets a persistent uncertainty in AML care. For a substantial proportion of older patients, clinicians lack clear evidence on whether stem cell transplantation or non-transplant therapy offers the better path following remission. By comparing these two approaches head-to-head, the study aims to generate data that can guide treatment decisions for this population.
Study Design and Endpoints
The trial will measure survival along with quality-of-life factors such as physical and cognitive function and frailty. This dual focus reflects an effort to capture not only how long patients live, but how well they function and maintain quality of life across treatment strategies.
Funding and Scope
The initiative is supported by $15 million from the Patient-Centered Outcomes Research Institute (搜索). With approximately 800 patients enrolled across 18 U.S. centers, the study represents a substantial multicenter effort to resolve a key clinical question in the management of older adults with AML.